Articles

As in any business, knowing current regulatory standards and your company’s status when compared to those standards is a key to remaining in compliance with both regulatory expectations and client expectations. One way to accomplish this comparison is to hire a third party auditor with the appropriate experience and knowledge to provide an independent perspective on the challenges homeopathic companies encounter under FDA regulations and client requirements.

The retention of reserve samples and their annual inspection records are a routine part of most cGMP inspections by the FDA. In the May 31, 2010 Tan Sheet, the publication reported that the FDA had warned Perrigo in a 483 posted May 28th, for failing to annually inspect retained samples.

RFID is a technology that uses radio waves to automatically identify objects. RFID technology can deliver many benefits, from tracking work in process to speeding throughput in a warehouse.

The HPCUS Council on Pharmacy (CoP) has discussed the appropriateness of warning statements for a number of homeopathic substances. The discussion only focused on low attenuations of three substances.

By Joerg Zimmer and Mark Land Introduction: In direct response to 9/11, the US Customs Service, now U.S. Customs and Border Protection (CBP) challenged the trade community to partner with…

The strong growth in natural products has led to an increasing number of homeopathic medicine departments in pharmacies across the country. Because there is still much controversy and misunderstanding by patients surrounding homeopathic medicine, U.S.Pharmacist asked Andy Bormeth, R.Ph. of the American Association of Homeopathic Pharmacists (AAHP), which represents the homeopathic drug industry and works as a liaison with FDA, state boards of pharmacy and pharmacy organizations, to discuss how pharmacists can best assist patients who use homeopathic medicines, the role homeopathy plays in health care, and to answer some basic questions regarding homeopathy.

On October 23, 2008 the FDA released its draft guidance on the new electronic submission system for drugs and establishment registrations.

Natural products’ consumers now have more choices than ever in the homeopathic medicinal category.

Current Good Manufacturing Practices (cGMPs) require manufacturers of homeopathic drug products to establish finished product specifications and to ensure product quality by testing products for conformance to specifications prior to release.

Final Product Testing of drug products has been a fixture in Title 21 of the Code of Federal regulations. Since the outset, this requirement has caused some difficulty for the manufacturers of homeopathic drug products (HDPs) since the final drug concentration in the final homeopathic dosage form often fell below the limits of measurement.